National Environmental PerformanceTrack
U.S. Environmental Protection Agency

OMB No. 2010-0032
Expiration Date 01/31/2010

2008 Performance Track Annual Performance Report

Pfizer Incorporated Terre Haute
A050045

Year 2 Annual Performance Report
Member Since 2001 (3rd Member Term)

SECTION A: GENERAL FACILITY INFORMATION

A.1 **Name of your facility:**

Pfizer Incorporated Terre Haute

A.2 **Name of your parent company:**

Pfizer, Inc.

A.3 **Facility contact person for the Performance Track program:**

Name:	Mr. David Rader
Title:	Director, Environmental Health & Safety
Phone:	(812) 299-2121 ext. 22551
Fax:	(646) 563-1452
Email:	david.rader@pfizer.com

A.4 **Facility location:**

Facility Address

Street Address:	100 Pfizer Drive
Address Cont:	
City:	Terre Haute
State:	IN
Zip Code:	47802

Mailing Address

Street Address:	P.O. Box 88
Address Cont:	
City:	Terre Haute
State:	IN
Zip Code:	47808

If your facility has multiple street addresses, please list any other addresses for its sites or buildin
411 E. Dallas Drive
Terre Haute, IN 47802

A.5 **Facility's website address (if any):**

http://

A.6 **Number of employees (full-time equivalents) who currently work in the facility:**

100-499

A.7 **For the purposes of where your facility would be listed in our Member Directory, please list the No American Industrial Classification System (NAICS) Code(s) that is (are) used to classify business a the facility:**

Primary	Secondary	Tertiary	Quaternary	Quinary
325412				

A.8.a **Have there been any changes to the activities, products, or services that take place at your facility**

Yes

Packaging of aseptic penicillin products will end in 2Q or 3Q 2009. Exubera inhalable insulin production w terminated by Pfizer in October 2007 and in 2008 Pfizer announced that all operations at the Terre Haute Facility will end in 2009. 2008 was primarily a year of decommissioning Exubera operations. The work forc was reduced by about 80% in 2008 and aseptic production will cease and operations colleagues will end t employment by the end of 2009. The facility will remain an active PT member through 2009, but this will b last annual report for the facility.

A.8.b **Provide the size and general description of your site:**

The facility is located on 1796 acres in a rural, industrial park setting. It consists of 9 production buildings a

31 production support facilities including offices, labs and warehouse space. The commercial facilities are located on approximately 25 acres. The remaining properties consist of 740 acres of classified forest and wildlife habitat and 700+ acres of tillable land located in rural Vigo County, Indiana.

Have there been any changes to the size or location of your facility?

No

A.9 **Have the environmental requirements applicable to your facility changed during this reporting peri**

No

A.10 **Is your facility using any of the following Performance Track regulatory and/or administrative incentives?**

No, the facility is not using any of these regulatory and/or administrative incentives

SECTION B: ENVIRONMENTAL MANAGEMENT SYSTEM

B.1.a **Is your facility certified to ISO 14001?**

No

B.2 **Note: On this facility's Application or a previous Annual Performance Report, they reported having independent assessment of their EMS in calendar year 2007. Since they are required to have an independent assessment every three years to remain a member of the Performance Track program they will next report their independent assessment in calendar year 2010.**

B.3 **EPA recommends that Performance Track members conduct an internal EMS assessment (partial complete) every year. Did you conduct one in calendar year 2008?**

Yes

Internal EMS Assessment #1

When was this EMS assessment?	July 2008
Which EMS elements were included in the audit?	Policy, Planning, Implementation, Checking, Management
Did the assessment cover the entire facility or part of the facility?	Entire Facility

B.4 **EPA recommends that Performance Track members conduct a regulatory compliance audit every Did your facility conduct any audits in calendar year 2008 to verify compliance with regulatory statutes?**

Yes

Regulatory Compliance Audit #1

When was this regulatory compliance audit?	January 2008
Which regulations were included in the audit?	Clean Air Act (CAA) Clean Water Act (CWA) Emergency Planning & Community Right-To-Know Act (EPC National Pollutant Discharge Elimination System (NPDES) Resource Conservation and Recovery Act (RCRA) Superfund Amendments and Reauthorization Act/Comprehensive Environmental Response, Compensatio and Liability Act (SARA/CERCLA) Toxic Substances Control Act (TSCA)

B.5 **Note: Facility will be asked to report other audits and inspections in their 3rd reporting year.**

B.6.a **Has your facility corrected all instances of potential non-compliance and EMS non-conformance identified during your audits and other assessments?**

No such instances identified

B.6.b **Performance Track members should have a Senior Management Review of their EMS every year. D this review take place in calendar year 2008?**

Yes

Who was the senior manager present at the review?

Name: Mr. Frank Foley

Title: Site Leader

B.6.c **Performance Track members should conduct a systematic identification and/or review of their environmental aspects at least once every two years. When was your last one conducted?**

July 2008

SECTION C: ENVIRONMENTAL PERFORMANCE RESULTS

Goal 1: Pfizer Incorporated Terre Haute's first goal is to reduce the facility's total water use.

This is a challenge goal.

C.1.a **Briefly describe your activities and achievements related to this goal or, if relevant, any circumstances that delayed progress this year.**

The facility eliminated use of noncontact,single pass cooling water from the Aseptic packaging opera by connecting the process to an unused chiller system. This has reduced annualized site water

consumption from 60 million gallons per year to 35 million gallons per year. NOTE then that actual w use has significantly decreased from 2006 levels, meeting the water goal on an absolute basis as we on a normalized basis and will not exceed 35 million gallons in 2009. The baseline, fixed demand for water (primarily sanitary uses) drives a significant increase in per dosage unit demand at these lowe production levels, even though the actual production efficiency has been improved through the elimir of cooling water demand - a 40% reduction in use. Pfizer will be closing the facilities in 2009.

Activities Conducted During 2007:

The significant reduction was acheived because single pass, non-contact cooling water was significa reduced through shutdown of a low production volume process that was a high volume water user in manufacturing area. In addition, the new Exubera production facility is a dry process and uses only a small volume of water for production support operations such as sterile water. In addition, general conservation measures were introduced after completing a water balance for the site, which identifie opportunities for users to improve their conservation practices.

C.1.b **Describe how your facility measured the quantity reported below (e.g., utility bills, manifests, purchasing receipts). If the quantity was derived from any assumptions or estimates, please describe these as well (e.g., multiplying monthly samples by the number of days in the month of emission factors, or converting volume to mass).**

Total water consumption is measured and provided to Pfizer by the water supplier's invoices. Note th the facility has normalized consumption to the number of Aseptic operations doses produced. Howe the data are skewed since Pfizer had significantly less Aseptic production in 2008 and because there no Exubera production in 2008. Pfizer terminated Exubera production in 2007.

Data Collection During 2007:

The site tracks total water consumption only and does not measure individual streams. Engineering estimates are provided based on operating time and pump/pipe volumes. Note that while total dose manufactured increased during the year the reported values in this report are absolute units and hav been normalized to the number of dosages.

C.1.c **Please report your facility's actual performance.**

Performance Data						
	Baseline	Year 1	Year 2	Year 3	Perform.	
Calendar Year	2006	2007	2008	2009	Goal	Units
Actual Quantity (per year)	183,000,000	69,670,000	48,000,000		n/a	Gallons
Change from baseline	NA	61.9%	73.8%			

C.1.d **Normalized progress toward goal.**

Normalized Total	Baseline	Year 1	Year 2	Year 3	Perform. Goal	Units
Normalizing Factor	1.0	8.74	0.863			
Normalized Quantity	183,000,000	7,971,396	55,619,930		155,550,000	Gallons
Basis for your Normalizing Factor:	normalized for number of doses produced					

Goal 2: Pfizer Incorporated Terre Haute's second goal is to reduce the facility's total (non-transportation energy use.

C.2.a **Briefly describe your activities and achievements related to this goal or, if relevant, any circumstances that delayed progress this year.**

An intensive energy conservation program was initiated in 2008 following the termination of Exubera production. The inactive Exubera areas were economized through reductions in lighting and HVAC t minimum safe, caretaker levels (pending facility divestiture) for spaces no longer in use and through optimization of HVAC and lighting needs in the active Aseptic production areas. Shifts were reduced seven day, 24 hour operations to four day, 24 hour operations and flexible work hours were initiated reduce the number of administrative support office hours, which further aided heating and lighting reductions. NOTE then that actual energy use has significantly decreased from 2006 levels, meeting energy goal on an absolute basis as well as on a normalized basis. Facilities have to be maintained minimal, fixed caretaker level until the facilities are sold and that fixed demand drives a significant increase in per dosage unit demand, even though the actual production efficiency has been more improved than the normalized value would imply. Nevertheless, the facility is achieving this commitm Pfizer will be closing the facilities in 2009.

Activities Conducted During 2007:

A significant relamping of warehouse space and packaging lines in addition to a transition to newer buildings and pump and HVAC optimization generated significant savings despite temporary reliance upon inefficient modular offices that were put into service pending completion of an energy efficient c space designed to Green Building standards. In addtion, the site shut down its wastewater treatment and switched to using the city wastewater treatment utility, allowing the site to remove from service a significant number of electric aeration units and pumps.

C.2.b **Describe how your facility measured the quantity reported below (e.g., utility bills, manifests, purchasing receipts). If the quantity was derived from any assumptions or estimates, please describe these as well (e.g., multiplying monthly samples by the number of days in the month of emission factors, or converting volume to mass).**

The energy sources were measured by the suppliers and documented as invoiced for each consump period. Note that the facility has normalized consumption to the number of Aseptic operations doses produced. However, the data are skewed since Pfizer had significantly less Aseptic production in 20(and because there was no Exubera production in 2008. Pfizer terminated Exubera production in 200

Data Collection During 2007:

The facility tracks overall consumption as billed by Duke Energy and calculates opportunities for ene conservation projects using engineering estimates followed by verification of overall consumption reduction. Note that the commitment was planned to be normalized to dosage volume. However, des increased dosage volume the site achieved absolute saving exceeding the commitment baseline. Therefore, the data reported are non-normalized absolute values.

C.2.c **Please report your facility's actual performance.**

Energy Generated Off-Site					
	Baseline	Year 1	Year 2	Year 3	
Calendar Year	2006	2007	2008	2009	Uni
Electricity Purchased					
Electricity from Grid/Utility	125,946	112,172	49,407		MMBtu
Electricity from Off-Grid			0		MMBtu

Renewable Sources					
Total Electricity Purchased	125,946	112,172	49,407		MMBtu
	If your facility purchases electricity from the grid, please confirm that electricity geographic region shown below is correct. If incorrect, ple contact the Performance Track Information Center. RFC West				
Steam *EPA will be determining the greenhouse gases associated with the generation of the steam that you purchase. We will be contacting you for additional information regarding the source of the steam generated.*	128,001	107,435	68,544		MMBtu
Total Energy Generated Off-Site	253,947	219,607	117,951		**MMBtu**

Sources of Energy Generated On-Site					
	Baseline	**Year 1**	**Year 2**	**Year 3**	
Calendar Year	**2006**	**2007**	**2008**	**2009**	**Uni**
Coal					
Natural Gas	2,894	8,900	5,660		MMBtu
Crude Oil					
Fuel Oil					
Diesel	24	3,422	122		MMBtu
Propane/LPG	462	296	320		MMBtu
Gasoline					
Hydrogen Powered Fuel Cells					
Natural Gas/Methane Powered Fuel Cells					
Biomass					
Biodiesel					
Solar					
Wind					
Landfill Gas					
Geothermal					
Hydroelectric					
Tire Derived Fuel					
Other Fuel or Source Specify:					
Total Energy Generated On-Site	3,380	12,618	6,102		**MMBtu**

C.2.d **Total energy use and associated greenhouse gas emissions.**

Actual Energy Use Total	**Baseline**	**Year 1**	**Year 2**	**Year 3**	**Perform. Goal**	**Units**
Total Renewable Energy Use	1,385	1,234	543.5		n/a	**MMBtus**
Total Non-Renewable Energy Use	255,942	230,991	123,510		n/a	**MMBtus**
Change from baseline	NA	9.8%	51.8%			
Total Energy Use	257,327	232,225	124,053		n/a	**MMBtus**

Metric Tons of CO_2 Equivalents	38,424	34,165	10,551		n/a	**MTCO2E**
Metric Tons of CO_2 Equivalents Offset due to Investments in Green Energy, e.g. green tags	0	0	0		0	**MTCO2E**
Net Metric Tons of CO_2 Equivalents	38,424	34,165	10,551		n/a	**MTCO2E**

Normalized Energy Use Total	**Baseline**	**Year 1**	**Year 2**	**Year 3**	**Perform. Goal**	**Units**
Normalizing Factor	1.0	8.74	0.863			
Total Energy Use	257,327	26,570	143,746		231,595	MMBtus
Net Metric Tons of CO_2 Equivalents	38,424	3,909	12,226		34,582	MTCO2E
Basis for your Normalizing Factor:	normalized for number of doses produced					

Goal 3: Pfizer Incorporated Terre Haute's third goal is to reduce the facility's generation of non-hazardou waste.

C.3.a **Briefly describe your activities and achievements related to this goal or, if relevant, any circumstances that delayed progress this year.**

The Aseptic operations reduced waste volumes using the Pfizer Right First Time, six sigma program make the processes more efficient and productive. This resulted in less line waste and thus reduced recycling, incineration and landfilling requirements. Production line waste was also eliminated with th shutdown of Exubera production. However, this information is masked over by the one time volume c waste generated during shutdown and decommissioning of the Exubera operations, which generatec substantial materials for recycling and reuse and a modest increase in landfilling and related incinera during a period when there was no Exubera production. As noted, these were unique, one time wast from the terminated operation and unrelated to ongoing production operations and thus skews the re (both normalized and non-normalized) to a much higher level than operations would normally produc Exubera production volume in 2008 was 100% lower (zero) and Aseptic production volume in 2008 v 14% lower than the 2006 production volume.

Activities Conducted During 2007:

The site undertook a study of site waste management methods for production and production suppor operations and was able to minimize waste volume through efficiency improvements in the packagin operations. The site also diverted pharmaceutical waste from landfilling to incineration. In addition, s reject materials were returned to the manufacturer. A 30% reduction in non-hazardous waste volume reflects the changes noted above and the shutdown of one of the site's manufacturing operations.

Note that an additional 5,896 tons of wastewater treatment pond remediation waste/soil mixture was generated from the closure of two wastewater ponds and removal of pond sediments. These are not included in the facility's actual performance since these were not generated by site operations and a non-recurring in nature. It is possible that other such waste/soil disposal may occur in the future as P

continues to work with IDEM and USEPA to implement wastewater treatment plant remediation/closu work plans for the remaining ponds.

C.3.b **Describe how your facility measured the quantity reported below (e.g., utility bills, manifests, purchasing receipts). If the quantity was derived from any assumptions or estimates, please describe these as well (e.g., multiplying monthly samples by the number of days in the month of emission factors, or converting volume to mass).**

Data were obtained from the weights supplied from the service providers' manifests and shipping rec Note that the facility has normalized consumption to the number of Aseptic operations doses produc However, the data are skewed since Pfizer had significantly less Aseptic production in 2008 and bec there was no Exubera production in 2008. Pfizer terminated Exubera production in 2007 and will be closing the facility in 2009.

Data Collection During 2007:

All data are obtained from weighed volumes tallied using internal spreadsheets, databases and manifest/shipping records. Note that the data provided in this report are not normalized data. Even th the site increased the volume of doses produced during the year reductions in waste volume were significant enough to achieve this commitment on an absolute basis.

C.3.c **Please report your facility's actual performance.**

Performance Data					
Waste Management Method	**Baseline**	**Year 1**	**Year 2**	**Year 3**	
	2006	2007	2008	2009	**Uni**
Landfill	528,500	402,448	455,099		Pounds
Incineration	445,825	502,887	407,647		Pounds
Reused/recycled off-site	1,242,978	535,591	1,980,007		Pounds

C.3.d **Summarized progress toward goal.**

Actual Total	**Baseline**	**Year 1**	**Year 2**	**Year 3**	**Perform. Goal**	**Units**
Total Non-Hazardous Waste	1,109	720.5	1,421		n/a	Tons
Change from baseline	NA	35.0%	-28.1%			

Normalized Total	**Baseline**	**Year 1**	**Year 2**	**Year 3**	**Perform. Goal**	**Units**
Normalizing Factor	1.0	8.74	0.863			
Total Non-Hazardous Waste	1,109	82.43	1,647		1,059	Tons
Basis for your Normalizing Factor:	normalized for number of doses produced					

Progress Towards Other Significant Aspects of your EMS

In the table below, please provide a narrative summary of progress made toward EMS objectives and targets o than those reported as Environmental Performance Goals. You may limit the summary to environmental aspect are significant and towards which progress has been made during the reporting year.

Do you have additional environmental aspects to report? No

SECTION D: PUBLIC OUTREACH AND PERFORMANCE REPORTING

D.1.a Please describe your process to identify potential community environmental concerns.

Pfizer has reached out to its neighbors and to the community at large, largely as a result of a 500-year stor event that caused significant flooding in the surrounding community. This was done through participation ir community meetings, meetings with media, regulatory agencies, the community govermental representativ and the residents and/or their representatives. Through this Pfizer was able to inform the parties of a poten release of PCB-containing sediments to the Jordan Creek watershed and was able to collect related poten concerns from the parties and to work with the community and regulatory agencies to implement corrective action to remediate the release in a timely manner.

D.1.b If you identified community environmental concerns, how did you respond to them?

Pfizer responded to concerns through the distribution of fact sheets, plot plans, development of work plans negotiation of access agreements with the neighbors to implement the work plans on their properties. This done in individual and group settings as well as with and without regulators as appropriate to the topic. All interested parties and stakeholders were kept informed of the remediation planning and progress and inpu solicited and addressed. Pfizer is accommodating community and regulatory agency concerns and input.

D.1.c Please describe how you informed the community about environmental matters related to your faci

The community has been informed using hand out materials, public meetings, private meetings, and group meetings, as well as through other channels of communication includine e-mail, letters and telephone conversations. Information was released to the news media and press. A public web site was established t keep the neighbors and all other interested parties in the community informed of the remediation progress. Points of contact have been made available through direct communications and the web site.

D.2 How did you share information with your community on your own facility's environmental performa including making your APR publicly available? Please check all that apply:

Meetings, Press Releases, Community Advisory Panel, Web Site

URL: http://www.jordancreekindiana.com

OMB No. 20

SECTION E: SELF-CERTIFICATION OF CONTINUED PROGRAM PARTICIPATI FOR ANNUAL PERFORMANCE REPORT

The U.S. Environmental Protection Agency is not yet in a position to accept electronic signatures and therefore requests a faxed, signed copy of the Section E page. Please complete Section E online, then print Section E usi the link on the Overview page. Section E should be signed by the senior manager of your facility and faxed it to t Performance Track Information Center at (617) 354-0463.

On behalf of Pfizer Incorporated Terre Haute, I certify that:

- I have read and agree to the terms and conditions as specified in the National Enviromental Performance Track Program Guide. This facility, to the best of my knowledge, continues to meet all program criteria;
- I have personally examined and am familiar with the information contained in this Annual Performance Re The information contained in this report is, to the best of my knowledge and based on reasonable inquiry, accurate, and complete;
- My facility has an environmental management system (EMS), as defined in the Performance Track EMS criteria, including systems to maintain compliance with all applicable federal, state, tribal, and local environmental requirements, in place at the facility, and the EMS will be maintained for the duration of the facility's participation in the program;
- My facility has conducted an objective assessment of its compliance with all applicable federal, state, trib and local environmental requirements; and the facility has corrected all identified instances of potential or actual noncompliance; and
- Based on the foregoing compliance assessments and subsequent corrective actions (if any were necessa my facility is, to the best of my knowledge and based on reasonable inquiry, currently in compliance with applicable federal, state, tribal, and local environmental requirements.

I agree that EPA's decision whether to accept participants into or remove them from the National Environment Performance Track is wholly discretionary, and I waive any right that may exist under any law to challenge EPA' acceptance or removal decision. I am the senior manager with responsibility for the facility and am fully authoriz execute this statement on behalf of the corporation or other legal entity whose facility is part of the National Environmental Performance Track program.

Signature/Date:	_____
Name:	Mr. Anibal Carlo
Title:	Operations Leader
Phone Number:	812-299-2121
E-Mail Address:	Anibal.Carlo@Pfizer.com
Facility Name:	Pfizer Incorporated Terre Haute
Facility Street Address:	100 Pfizer Drive Terre Haute, IN 47802
Mailing Address:	100 Pfizer Drive Terre Haute, IN 47802
Performance Track ID#:	A050045